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The hepatitis B virus (HBV) PreS mutations C1653T, T1753V, and A1762T/G1764A were reported as a
strong risk factor of hepatocellular carcinoma (HCC) in a meta-analysis. HBV core promoter overlaps partially
with HBx coding sequence, so the nucleotide 1762 and 1764 mutations induce HBV X protein (HBx) 130 and
131 substitutions. We sought to elucidate the impact of HBx mutations on HCC development. Chronically
HBV-infected patients were enrolled in this study: 42 chronic hepatitis B (CHB) patients, 23 liver cirrhosis
(LC) patients, and 31 HCC patients. Direct sequencing showed HBx131, HBx130, HBx5, HBx94, and HBx38
amino acid mutations were common in HCC patients. Of various mutations, HBx130HBx131 (double)
mutations and HBx5HBx130HBx131 (triple) mutations were significantly high in HCC patients. Double
and triple mutations increased the risk for HCC by 3.75-fold (95% confidence interval [CI]  1.101 to 12.768,
P 0.033) and 5.34-fold (95% CI 1.65 to 17.309, P 0.005), respectively, when HCC patients were compared
to CHB patients. Functionally, there were significantly higher levels of NF-B activity in cells with the HBx5
mutant and with the double mutants than that of wild-type cells and the triple-mutant cells. The triple
mutation did not increase NF-B activity. Other regulatory pathways seem to exist for NF-B activation. In
conclusion, a specific HBx mutation may contribute to HCC development by activating NF-B activity. The
HBx5 mutation in genotype C2 HBV appears to be a risk factor for the development of HCC and may be used
to predict the clinical outcomes of patients with chronic HBV infection.
Hepatitis B virus (HBV) infection is a global health issue, with
two billion people infected worldwide and 350 million suffering
from chronic HBV infection (18). Chronic HBV infection is
known as the most common underlying etiology of hepatocellular
carcinoma (HCC) (2) and can further progress to liver cirrhosis
(LC) and HCC. However, the pathogenesis of these HBV-related
diseases has not been fully clarified. The disease progression may
depend on complex and multistep mechanisms.
In an HBV management consensus report, the National
Institutes of Health (NIH) suggested risk factors associated
with the increased risk of HCC and cirrhosis in chronic HBV-
infected patients (20). That report described the HCC risk
based on demographic factors, environmental factors, and viral
factors and classified them using the scoring system of evi-
dence-based studies. The association between HBV mutations
and HCC has not been fully investigated. Recently, the HBV
PreS mutations C1653T, T1753V, and A1762T/G1764A were
reported as strong risk factors for HCC in a meta-analysis (19).
Mutations of HBV have been considered as an escape mech-
anism from the host immune system and may affect the onco-
genic potential of chronic HBV diseases.
HBV X is the smallest of four kinds of HBV functional
genes, but it expresses a 154-amino-acid multifunctional pro-
tein (HBx), with an N-terminal negative regulatory/antiapop-
totic domain and a C-terminal transactivation/proapoptotic
domain. The gene also seems to be associated with modulation
of a wide range of cellular functions, leading to HCC (5).
Moreover, of the four open reading frames, the X gene re-
mains enigmatic. There are conflicting suggestions about the
functional activity of HBx. HBx induced HCC in certain trans-
genic mice in vivo (15, 30) and in vitro (11, 25). Nevertheless, there
are other transgenic lineages in which HBx does not lead to HCC
development (3, 24). Many reports suggest that HBx is a multi-
functional regulatory protein that directly or indirectly interacts
with a variety of targets and mediates many cellular functions.
Thus, the goals of the present study were to elucidate the char-
acteristics of HBx mutations according to the clinical phase of
HBV infection and to examine the functions of significant HBx
mutations that appear to be related to HCC pathogenesis.
MATERIALS AND METHODS
Study subjects. Patients with chronic HBV infection were enrolled in the
present study. There were 42 chronic hepatitis B disease (CHB) patients, 23 LC
patients, and 31 HCC patients. The HBV-related etiology was confirmed based
on clinical and radiologic findings, laboratory tests, and pathological findings
(i.e., serum alanine aminotransferase, HBsAg, HBeAg, HBV DNA, and liver
biopsy). All patients’ samples were divided into aliquots and kept frozen at
70°C until used.
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The study protocol conformed to the 1975 Declaration of Helsinki and was
approved by the Institutional Review Board of the Yonsei University Health System.
Sequencing of HBV DNA from the subjects. HBV DNA was extracted from
serum samples by using a DNA minikit (Qiagen, Hilden, Germany) or a Quick-
Gene DNA Tissue Kit S (Fujifilm, Tokyo, Japan). Nested PCR was performed to
amplify HBV X gene. The primers for HBV X gene amplification were as
follows: sense (5-CATGCGTGGAACCTTTGTG-3; positions 1233 to 1251)
and antisense (5-CTTGCCTKAGTGCTGTATGG-3; positions 2072 to 2053)
for the first PCR amplification and sense (5-TCCTCTGCCGATCCATACTG-
3; positions 1254 to 1263) and antisense (5-CAGAAGCTCCAAATTCTTTA
TA-3; positions 1937 to 1916) for the second PCR amplification.
PCR premix (Accupower Pfu PCR PreMix; Bioneer, Daejun, Korea) with a
MyGenie 96 Gradient Thermal Block (Bioneer, Daejun, Korea) were used to
produce an 839-bp amplicon. A 683-bp amplicon of the second nested PCR was
identified in 1% agarose gel electrophoresis stained with ethidium bromide. PCR
products were purified and then sequenced by an ABI 3730 automated sequencer
(Applied Biosystems, Foster City, CA) with a BigDye Terminator v3.1 sequenc-
ing kit (Applied Biosystems). If primary PCR was not successful, the supplemen-
tary primer sets described by Kim et al. (17) were also used for direct sequencing.
All sequencing data were analyzed based on the consensus HBV sequence
(GenBank accession no. GQ475316) of a chronic HBV carrier patient without
antiviral therapy. The sequencing data were multiply aligned and analyzed by
CLUSTAL W and Bioedit v7.0.5 software (Ibis Therapeutics, Carlsbad, CA).
HBV genotyping. Deduced X gene base pairs were compared to several con-
sensus sequences of HBV genotypes, and a phylogenetic tree was constructed by
the neighbor-joining method. Phylogenetic and molecular evolutionary analyses
were performed using MEGA version 4.0.2 (The Biodesign Institute, Tempe,
AZ). The genetic distances were estimated by Kimura’s two-parameter method.
The reliability of the phylogenetic tree analysis was assessed by the interior
branch test with 1,000 replicates.
Construction of HBx plasmid. Three most frequent HBx mutations in HCC
patients were HBx131, HBx130, and HBx5 mutations in that order. Therefore,
four different types of plasmids were constructed: (i) wild-type HBx, (ii) single
amino acid mutants of HBx (HBx5; G1386A and V5M), (iii) a double amino acid
mutants of HBx (HBx130HBx131; A1762TG1764A and K130MV131I),
and (iv) triple amino acid mutants of HBx (HBx5HBx130HBx131;
G1386AA1762TG1764A and V5MK130MV131I). All plasmids were
produced based on a 1.2-mer HBV construct within the pGEM4Z vector (kindly
provided by Kyun Hwan Kim) with the appropriate site-directed mutagenesis prim-
ers. PCR products were treated with the restriction enzyme DpnI or NcoI/HindIII
and then transformed into XL10 Gold Ultra Competent cells (Stratagene, Cedar
Creek, TX) according to the manufacturer’s instructions. All mutant clones were
verified by sequencing both strands of DNA within the regions of interest.
Cell cultures and transfection into Huh7 cells. Nucleic acids were prepared by
Escherichia coli transformation using Qiagen plasmid midikits, and Huh7 cells
were cultured in Dulbecco modified Eagle medium (Gibco) at 37°C in 5% CO2.
Huh7 cells were transiently transfected with pGEM4Z, HBx wild-type, HBx5
mutant, HBx double-mutant, and HBx triple-mutant constructs, using Lipo-
fectamine LTX and Plus reagents (Invitrogen, Carlsbad, CA). All experiments
were performed in triplicate.
Detection of HBV replication by using HBV DNA, HBsAg, and HBeAg expres-
sion. Real-time PCR was used to determine HBV DNA replication activity in each
group of transfected cells. DNA was extracted from transfected cells transfected with
each construct, and then the purity and quantity of DNA were measured by using
Nanodrop (Thermo Fisher Scientific, Inc., Wilmington, DE). Real-time PCR am-
plifications were carried out using the ABI 7000 system (Applied Biosystems). The
100-ng/l template was processed with SYBR green I and the primers HBs-F
(5-CCTCTTCATCCTGCTGCT-3) and HBs-R (5-AACTGAAAGCCAAACAG
TG-3). Real-time PCR amplification was carried out by using an ABI 7000 system
(Applied Biosystems) using 2 SYBR green mix (Applied Biosystems). The thermal
conditions for SYBR real-time PCR were 95°C for 2 min, followed by 40 cycles of
15 s at 95°C and 1 min at 60°C. The values were normalized to GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase) expression in each sample.
The total protein concentration in harvested cell lysates and in the superna-
tants of transfected Huh7 cells were determined by bicinchoninic acid kit (Pierce,
Rockford, IL). The corrected HBsAg and HBeAg levels were determined by
using an Architect i2000 analyzer (Abbott Diagnostics, Abbott Park, IL).
NF-B luciferase reporter gene assay. To determine the NF-B activity,
cotransfection with NF-B luciferase vector and HBx constructs was performed
using Lipofectamine LTX and Plus reagents (Invitrogen). Cells were harvested 2
days after transfection, and then the luciferase activity was detected by using the
dual luciferase reporter assay system (Promega, San Luis Obispo, CA) on a
Victor X4 multilabel plate reader (Perkin-Elmer Life Sciences, Shelton, CT). All
luciferase data were normalized with the corresponding Renilla luciferase activ-
ity. Each experiment was performed in triplicate.
Statistical analysis. SPSS 12.0 (SPSS, Inc., Chicago, IL) was used for statistical
analyses. Statistical analysis were performed by using the chi-square test or the
Fisher’s exact test for categorical variables and the Mann-Whitney U-test or
one-way analysis of variance for continuous variables. P values of 0.05 were
considered significant.
RESULTS
Basic characteristics of study subjects. The basic character-
istics and HBx mutations of enrolled patients are summarized
in Tables 1 and 2, respectively. There were some significant
differences according to the clinical phase of HBV infection.
The average age of HCC patients was higher than that of CHB
patients (P  0.001) but was not different from that of LC
patients (P 0.275). The levels of HBV DNA in HCC patients
were lower than those in CHB patients (P  0.002) but were
not different from those in LC patients (P  0.872). HBeAg
status was different among three clinical phases of HBV infec-
tion (P  0.002). The most common HBx mutation in HCC
patients was followed by HBx131, HBx130, HBx5, HBx94, and
HBx38. The incidence of the HBx5HBx130HBx131 triple
mutations in HCC patients increased with age (Table 3).
HBx mutations according to the status of HBV infection.
Patients had at least 1 and a maximum of 27 amino acid
mutations. The frequency of all HBx mutations was found in
6.28 	 4.27 (means 	 the standard deviation [SD]). The inci-
dence of each HBx mutation related to the clinical diagnosis of
HBV infections is presented in Fig. 1. A total of 603 HBx
mutations were evaluated: 250 in CHB patients (n  42), 167
in LC patients (n 23), and 186 in HCC patients (n 31). The
mean frequencies for HBx mutations according to clinical di-
TABLE 1. Characteristics of HBx mutations according to clinical diagnosisa
Parameter CHB LC HCC Pb
No. of patients 42 23 31
Mean age (yr) 	 SD 43.6 	 10.7 51.7 	 7.8 55.6 	 7.8 0.007*
Sex ratio (males:females) 2 (28:14) 2.3 (16:7) 5.2 (26:5) 0.241†
HBV DNA (IU/ml)c 	 SD 162,785,477 	 222,839,000 21,778,882 	 77,209,447 841,788 	 1,558,362 0.001*
HBeAg ratio (no. positive:no. negative) 2.8 (31:11) 1.1 (12:11) 0.5 (10:21) 0.002†
Mean no. of HBx mutations 	 SD 5.95 	 5.04 7.26 	 4.7 6 	 2.37 0.455*
Range (no.) of HBx mutations 1–25 3–27 1–11
a CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma.
b As determined by one-way analysis of variance (*) or chi-square test (†).
c IU, international units.
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agnosis were 5.95 	 5.04 in CHB patients, 7.26 	 4.7 in LC
patients, and 6 	 2.37 in HCC patients. Amino acid deletions
were noted in one CHB patient (deletion from HBx129 to
HBx134) and two HCC patients (deletion from HBx127 to
HBx131; deletion from HBx128 to HBx132). In HCC patients,
the most common HBx mutations were HBx130HBx131 dou-
ble mutations (71%), followed by HBx5HBx130HBx131
triple mutations (41.9%) and HBx94HBx130HBx131 triple
mutations (35.5%). The number of patients with single muta-
tions (HBx130, HBx131, HBx5, and HBx94) was very low
or zero. The quadruple mutations (HBx5HBx94HBx130
HBx131) were observed in 12.9% of HCC patients. Interestingly,
HBx5HBx130HBx131 triple mutations were significantly
more common in HCC patients than in CHB patients. HBx mu-
tations showed significant differences by clinical phases.
Risk assessment of double mutations and triple mutations.
Odds ratios were calculated based on the number of patients
with double or triple mutations (Table 4). Generally, the odds
ratio of HCC patients with triple mutations was higher than
that of HCC patients with double mutations. The odds ratio
was not statistically significant when HCC patients were com-
pared to CHB patients, including LC patients. However, dou-
ble and triple mutations were significant risk factors for HCC
incidence compared to CHB patients only. Considering LC as
a pre-HCC disease status, double and triple mutations were
also significantly associated with HCC incidence.
HBV genotype analysis with phylogenetic tree constructs. A
neighbor-joining method was used to analyze HBV genotype.
As expected, enrolled patients were determined as HBV ge-
notype C2, which is known to be the most common genotype in
Korea. A circular phylogenetic tree is presented in Fig. 2.
HBV DNA and viral protein assay of each construct. The
total HBV DNA levels in cells transfected with HBx wild type
and three mutant types were analyzed. There were no signifi-
cant differences in HBV DNA levels between each HBx mu-
tant and the HBx wild type (P
 0.05). HBV protein expression
was analyzed by HBsAg and HBeAg assays in triplicate. A
negative control yielded negative HBsAg and HBeAg results.
There was no significant difference in the protein levels be-
tween the supernatants of the wild-type DNA transfected cells
and the mutant DNA transfected cells (Fig. 3). Corrected
levels of HBsAg and HBeAg were calculated according to the
total protein concentration.
NF-B activity by luciferase reporter gene assay. The lucif-
erase activity was normalized by the activity of wild-type HBx-
transfected cell lysates (relative luciferase activity). The results
are expressed in Fig. 4 as means (bar)  the SD (line) of at
least three experiments. There were significantly higher levels
of NF-B activity in cells with the HBx5 mutation and
HBx130HBx131 double mutations than in wild-type cells and
those with the HBx5HBx130HBx131 triple mutations (Fig.
4). Cells with triple mutations did not show a significant dif-
ference in NF-B activity compared to wild-type cells.
TABLE 2. Common HBx mutations (4 times incidence)
Condition and
mutation site
Total no.
of mutations Frequency (%)
CHB
HBx131 28 66.7
HBx130 27 64.3
HBx42 9 21.4
HBx36 8 19.0
HBx48 7 16.7
HBx79 7 16.7
HBx92 7 16.7
HBx94 7 16.7
HBx52 6 14.3
HBx106 6 14.3
HBx127 6 14.3
HBx5 5 11.9
HBx38 5 11.9
HBx12 4 9.5
HBx80 4 9.5
HBx101 4 9.5
HBx116 4 9.5
LC
HBx131 23 100.0
HBx130 20 87.0
HBx94 13 56.5
HBx5 10 43.5
HBx79 7 30.4
HBx42 6 26.1
HBx36 6 26.1
HBx38 5 21.7
HBx127 4 17.4
HBx12 4 17.4
HBx101 4 17.4
HBx102 4 17.4
HCC
HBx131 28 90.3
HBx130 27 87.1
HBx5 13 41.9
HBx94 12 38.7
HBx38 8 25.8
HBx36 6 19.4
HBx127 5 16.1
HBx101 4 12.9
HBx52 4 12.9
TABLE 3. Incidence of double and triple HBx mutations by clinical diagnosis
Subject age range (yr)
No. (%) of HBx mutationsa
CHB (n  42) LC (n  23) HCC (n  31)
Total Double Triple Total Double Triple Total Double Triple
20–30 5 3 (60) 0 (0) 0 0
31–40 10 4 (40) 1 (10) 1 0 (0) 1 (100) 1 1 (100) 0 (0)
41–50 15 5 (33.3) 4 (26.7) 9 5 (55.6) 3 (33.3) 7 3 (42.9) 3 (42.9)
51–60 10 8 (80) 0 (0) 11 4 (36.4) 5 (45.5) 14 6 (42.9) 5 (35.7)
61–70 2 2 (100) 0 (0) 2 1 (50) 1 (50) 9 4 (44.4) 5 (55.6)
a CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; Double, HBx130HBx131 mutations; Triple, HBx5HBx130HBx131 mutations.
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DISCUSSION
HBx is known to be a multifunctional protein that not only
activates transcriptional transactivation but also mediates cell
growth via proliferation and apoptosis (5). Moreover, the HBx
protein is potentially oncogenic via multistep carcinogenesis,
modifies apoptosis, inhibits nucleotide excision, repairs dam-
aged cellular DNA, and modulates transcriptional activation of
cellular growth regulating genes (4).
FIG. 1. Percentage of HBx mutations according to clinical diagnosis of HBV infection. Abbreviations: CHB, chronic hepatitis B; LC, liver
cirrhosis; HCC, hepatocellular carcinoma.
TABLE 4. Odds ratios for HCC incidence of double and triple mutations
Comparisona
No. of mutations for various conditionsb Odds ratio
HCC No HCC HCCLC No HCCLC Mean 95% CIc P
HCC vs. CHB
Double mutations 27 27
No double mutations 4 15
Odds ratio 3.75 1.101–12.768 0.033
Triple mutations 13 5
No triple mutations 18 37
Odds ratio 5.344 1.65–17.309 0.005
HCCLC vs. CHB
Double mutations 47 22
No double mutations 7 15
Odds ratio 4.578 1.634–12.825 0.003
Triple mutations 23 5
No triple mutations 31 37
Odds ratio 5.49 1.867–16.142 0.001
HCC vs. CHBLC
Double mutations 27 47
No double mutations 4 18
Odds ratio 2.585 0.793–8.432 0.126
Triple mutations 13 15
No triple mutations 18 50
Odds ratio 2.407 0.962–6.026 0.091
a Double mutations, HBx130HBx131; triple mutations, HBx5HBx130HBx131.
b CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma.
c CI, confidence interval.
VOL. 18, 2011 IMPACT OF HBx MUTATIONS ON HEPATOCELLULAR CARCINOMA 917
To date, the clinical impact of HBx mutation has not been
clearly defined. Specific regions of HBx mutations or deletions
are reported to have an association with HBV pathogenesis in
the sera (17, 28) or liver tissues (32) of CHB patients. How-
ever, the exact impact of specific HBx mutation on chronicity
or carcinogenesis remains unclear.
We found that the incidence of HBx5 mutation was signifi-
cantly higher in our HCC patients than in CHB patients. How-
ever, all patients with a HBx5 mutation had HBx130HBx131
double mutations, too. The frequency and function of HBx5
mutation have not been determined in terms of the oncogenic
potential. Further studies of the HBx5 mutation with or with-
out HBx130HBx131 double mutations are needed to under-
stand the elucidate role of HBx5 mutation.
HBV DNA sequences differ between HBV genotypes or
subgenotypes, so we believe that the HBx5 mutation might be
characteristically related to genotype C2 in Korean HCC pa-
tients. Almost all Korean HBV genotypes are known to be
HBV C2 (16) and, unfortunately, patients with HBV C2 ge-
notype tend to rapidly progress to cirrhosis or HCC, and it can
commonly cause complications in younger patients (12).
There have been several studies on the clinical correlations
between HBx mutations and HCC. For example, Yeh et al.
(29) reported that HBx codon 31 was detected more frequently
in patients with HCC. Muroyama et al. (21) reported that an
HBx codon 38 change in genotype C is an independent risk
factor for HCC development. Shinkai et al. (26) reported that,
regardless of HBeAg status, the T1653 mutation increases the
risk of HCC in Japanese patients with HBV/C2. Choi et al. (6)
reported that only the B1499 (C or G or T1499) mutation was
significantly associated with HCC. However, there has been no
established consensus on or mechanism of which HBx muta-
FIG. 2. Phylogenetic tree of enrolled patients developed using the neighbor-joining method. Phylogenetic and molecular evolutionary analyses
were performed using MEGA version 4.0.2 (The Biodesign Institute). The genetic distances were estimated by Kimura’s two-parameter method.
The reliability of the phylogenetic tree analysis was assessed by using the interior branch test with1,000 replicates. Abbreviations: CHB, chronic
hepatitis B disease patient; LC, liver cirrhosis patient; HCC, hepatocellular carcinoma patient.
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tion or deletion directly affects the pathogenesis of HCC. This
might be attributed to differences in HBV genotype, the level
of HBV DNA, coinfection of other viruses, and effects of host
factors.
Our study showed that double mutations of HBV at nucle-
otide 1762 (A3T) and 1764 (G3A) in the basal core pro-
moter (BCP) region were the most common mutation types in
HCC patients. Because double mutations in the BCP region
also exist in the coding sequence of HBV X gene, these mu-
tations convert K to M at position 130 and V to I at position
131 in the overlapping X-open reading frame gene product. To
date, these double mutations have been suggested to arrest the
transcription of the precore RNA but without a serious impact
on the transcription of the pregenomic RNA (23). Cell trans-
fection experiments on the T1762/A1764 double mutations
showed conflicting results regarding the increase in viral rep-
lication (9). However, double mutations in the BCP region
were suggested to be associated with HCC development (7, 10,
13), and this finding has been supported by a prospective co-
hort study (8).
CHB patients without cirrhosis but with HBx5HBx130
HBx131 triple mutations showed a significant risk for HCC
development. Also, CHB patients with HBx5HBx130
HBx131 triple mutations showed a somewhat higher risk for
HCC than those with HBx130HBx131 double mutations.
The fifth amino acid of HBx is located in the negative reg-
ulatory region, which is known as a dispensable region for
transactivation. HBx5 mutation cell line experiments showed
no differences in viral replication activity whether they had
double mutations or the HBx5 mutation. However, the relative
transcriptional activity of NF-B was significantly higher in
patients with an HBx5 single mutation and HBx130HBx131
double mutations than in patients with wild-type HBx and in
those with HBx5HBx130HBx131 triple mutations. This
FIG. 3. Protein expression of cells transiently transfected with wild-type and HBx mutant constructs. (A) HBsAg expression; (B) HBeAg
expression.
FIG. 4. Relative luciferase assays showing the activity of NF-B in wild-type and HBx mutant Huh7 cells.
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might suggest that NF-B was not significantly activated by
triple mutations in HCC patients. Nevertheless, both the HBx5
mutation and the HBx130HBx131 double mutation could
activate the NF-B signaling pathway. This phenomenon im-
plies that HBx5 mutation does not directly influence HBV
replication but might be associated with modulation of the
cellular signaling pathway. In addition, NF-B activity was
characteristically affected by the existence of HBx5 mutation.
In fact, HBx5 mutation was always found with double muta-
tions in all clinical phases of HBV infection. This also implies
that an independent outbreak of HBx5 mutation may burden
HBV life cycle and may not be affordable for viral immune escape
from the host defense system. However, HBx5HBx130
HBx131 triple mutations did not increase NF-B activity. We
found through repeated experiments that the NF-B activity in
cells with triple mutations was almost the same as in cells with
wild-type HBV. This result suggested that a specific HBx muta-
tion might be related not only to the major NF-B signaling
pathway but also to other signaling pathways. Triple mutations
seem to burden the life cycle of HBV and be associated with
tumorigenesis. A triple mutation might also change the HBx
protein structure, possibly affecting NF-B activity. The present
study focused on the NF-B signaling pathway because it seems
to have a central function in liver homeostasis, pathophysiology,
and regulation of the inflammation-fibrosis-cancer axis (27).
NF-B also plays a role in the development of HCC (14). HBV
and HBx have been known to activate NF-B (22, 31), but it is
unclear whether specific HBx mutation can affect NF-B activity.
So, we focused on determining whether a significant HBx muta-
tion can affect NF-B activity. Human NF-B that regulates a
number of oncogenic genes is associated with tumorigenesis in
mammalian cells through the regulation of a number of onco-
genic genes (1). Our findings suggest that a specific HBx mutation
could modulate the NF-B signaling pathway, which is possibly
associated with tumorigenesis. The HBx5 mutation may enhance
the oncogenic potential to progress from a chronic liver disease
to HCC.
In conclusion, the HBx130HBx131 double mutation was
the most common HBx mutation occurring in HCC patients
with chronic HBV infection, followed by the HBx5HBx130
HBx131 triple mutation. The HBx5 mutation was more fre-
quently observed in HCC patients than CHB patients. An
HBV construct containing wild-type HBx and each of three
types of HBx mutation was transiently transfected, and the
effect of HBx mutation on the viral replication, HBV protein
expression, and NF-B activity was observed. As a result,
the HBx5 single mutation, HBx130HBx131 double muta-
tions, and HBx5HBx130HBx131 triple mutations were
not directly associated with either viral protein expression or
viral replication activity. However, the HBx5 mutation and
HBx130HBx131 double mutations appear to modulate the
transcriptional transactivating function of the NF-B signaling
pathway.
We showed here that the HBx5 single mutation and
HBx130HBx131 double mutation increased NF-B activity
and that the HBx5HBx130HBx131 triple mutation did not
increase NF-B activity. Thus, there seems to be another path-
way that regulates NF-B activation by HBx mutation. Also,
older HCC patients were more likely to have the HBx130
HBx131 double mutations and HBx5HBx130HBx131 triple
mutations than younger HCC patients. Therefore, patient age
should be considered as a factor affecting the development of
HCC. The HBx5 mutation in genotype C2 may be a risk factor
for HCC development and appears to serve as a potential
molecular marker for predicting the clinical outcomes of pa-
tients with chronic HBV infection.
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Volume 18, no. 6, p. 914 –921, 2011. Page 919, column 2, lines 13 to 17 should read: “However, the relative transcriptional activity of
NF-B was significantly higher with an HBx5 single mutation and HBx130HBx131 double mutations than with wild-type HBx and
with HBx5HBx130HBx131 triple mutations in transfected cells.”
Page 919: Figure 4 should appear as shown below.
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